This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective. To estimate potential costs and benefits of routinely using tandem mass spectrometry (MS/MS) to screen newborns for inborn errors of metabolism.
Method. Analysis of costs and benefits resulting from use of MS/MS in screening of 32 000 newborn infants using data from the Kaiser Permanente Medical Care Program of Northern California plus other published data.
Setting. A large health maintenance organization.
Results. In the base scenario, the cost per quality-adjusted life year saved by MS/MS screening was $5827; in the least favorable scenario, this cost was $11 419, and in the most favorable scenario, $736.
Conclusion. Costs per quality-adjusted life year saved by MS/MS screening for inborn errors of metabolism compare favorably with other mass screening programs, including those for breast and prostate cancer.
- costs and cost analysis
- homocystinuria
- maple syrup urine disease
- metabolism
- inborn errors
- neonatal screening,
- spectrum analysis
- mass
- Received January 25, 2002.
- Accepted June 19, 2002.
- Copyright © 2002 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD
- Economic Evaluation of Tandem Mass Spectrometry Newborn Screening in Australia
- False-positive Results in Expanded Newborn Screening
- Introduction to the Newborn Screening Fact Sheets
- Comprehensive Cost-Utility Analysis of Newborn Screening Strategies
- Financing State Newborn Screening Programs: Sources and Uses of Funds
- Research for Newborn Screening: Developing a National Framework
- Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health
- Management of Hyperbilirubinemia: Quality of Evidence and Cost
- Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness Analysis